FDA Inspection 1015476 — Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy

Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy — FEI 3004486825

The FDA completed an inspection of Snyder Mark Drugs Roselle, Inc. d.b.a. Mark Drugs Pharmacy on May 22, 2017 in Roselle, IL. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 6 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
May 22, 2017
Fiscal Year
2017
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Roselle, IL (United States)

Citations

IDCFRDescription
115921 CFR 211.28(a)Clothing appropriate for duties performed
143421 CFR 211.42(c)(10)(iv)Environmental Monitoring System
145121 CFR 211.113(b)Procedures for sterile drug products
188521 CFR 211.165(b)Microbiological testing
191421 CFR 211.166(a)Lack of written stability program
193221 CFR 211.167(a)Sterility/pyrogen-free testing